The role of adjuvants in retroviral vaccines.
The global HIV epidemic continues unchecked. Reports to the World Health Organization's Global Programme on AIDS indicate that more than 14 million persons have become infected with HIV and more than two million have died with AIDS. The spread of AIDS has generated a worldwide mandate for the development of safe and effective vaccines against HIV. Vaccines have been the most effective defense against other viral diseases such as polio and smallpox. However, the development of a vaccine against HIV-1 is a formidable task due to the variation of the virus, inadequate animal models of HIV disease, and the lack of correlates of protective immunity. Several candidate HIV vaccines are composed of synthetic, recombinant, or highly purified subunit antigens. Vaccines composed of subunit antigens generally are considered to be safer than traditional whole-killed or live-attenuated vaccines. However, purified subunit vaccines often are inherently less immunogenic than traditional vaccines. Immunologic adjuvants are agents that act generally to enhance specific immune responses to vaccine antigens. Formulation of experimental HIV vaccines with potent immunologic adjuvants is an attractive approach for amplifying and directing immune responses to highly purified antigens. Alum adjuvants, consisting of aluminum salts, first described in the 1920s, remain the only adjuvants in U.S.-licensed vaccine formulations. Novel adjuvants now undergoing preclinical and clinical testing with experimental subunit vaccine include detoxified lipid A, adjuvant emulsions, liposomes, biodegradable microspheres, muramyl peptides, and saponins. Adjuvants have been shown to elicit cytotoxic T-cell responses as well as antibody to subunit antigens.(ABSTRACT TRUNCATED AT 250 WORDS)
Vogel
F R
FR
Vaccine and Prevention Research Program, NIAID, Bethesda, MD 20892, USA.
D016915:AIDS Vaccines / Q000276:immunology; D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005260:Female; D000882:Haplorhini; D006801:Humans; D008297:Male; D018448:Models, Immunological; D011817:Rabbits; D012190:Retroviridae / Q000276:immunology*; D018449:SAIDS Vaccines / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D018449:SAIDS Vaccines; D014765:Viral Vaccines